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Objectives: Previous fMRI studies have demonstrated that glucose decreases the hypothalamic BOLD response in
humans. However, the mechanisms underlying the CNS response to glucose have not been deﬁned.We recently
demonstrated that the slowing of gastric emptying by glucose is dependent on activation of the gut peptide
cholecystokinin (CCK1) receptor. Using physiological functional magnetic resonance imaging this study aimed
to determine the whole brain response to glucose, and whether CCK plays a central role.
Experimental design: Changes in blood oxygenation level-dependent (BOLD) signal weremonitored using fMRI in
12 healthy subjects following intragastric infusion (250 ml) of: 1 M glucose + predosing with dexloxiglumide
(CCK1 receptor antagonist), 1 M glucose + placebo, or 0.9% saline (control) + placebo, in a single-blind,
randomised fashion. Gallbladder volume, blood glucose, insulin, and GLP-1 and CCK concentrations were deter-
mined. Hunger, fullness and nausea scores were also recorded.
Principal observations: Intragastric glucose elevated plasma glucose, insulin, and GLP-1, and reduced gall
bladder volume (an in vivo assay for CCK secretion). Glucose decreased BOLD signal, relative to saline, in
the brainstem and hypothalamus as well as the cerebellum, right occipital cortex, putamen and thalamus.
The timing of the BOLD signal decreasewas negatively correlatedwith the rise in blood glucose and insulin levels.
The glucose + dex arm highlighted a CCK1-receptor dependent increase in BOLD signal only in the motor cortex.
Conclusions: Glucose induces site-speciﬁc differences in BOLD response in the human brain; the brainstem and
hypothalamus show a CCK1 receptor-independent reductionwhich is likely to bemediated by a circulatory effect
of glucose and insulin, whereas the motor cortex shows an early dexloxiglumide-reversible increase in signal,
suggesting a CCK1 receptor-dependent neural pathway.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Obesity is now one of the major public health problems facing the
world. In 2005, 400 million adults were obese, and this is projected toysiological magnetic resonance
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. This is an open access article underincrease to 700 million by 2015 (www.who.int). This “epidemic” has
prompted major scientiﬁc efforts to determine the mechanisms under-
lying the regulation of food intake in order to facilitate the development
of effective therapies for obesity. A particular focus has been applied
to nutrient-induced gut-to-brain signalling mechanisms. In human
research, the development of blood-oxygenation-level-dependent
(BOLD) functional magnetic resonance imaging (fMRI) has resulted in
the identiﬁcation of a number of homeostatic and non-homeostatic
brain regions associated with the regulation of appetite (Gibson et al.,
2010). However, to date, the focus of these human studies has largely
been the evaluation of higher centre cognitive responses to food cues
(such as images of palatable food), rather than the physiological re-
sponses to meal ingestion. The more recent application of the phys-
iological MRI (physMRI) technique (Jones et al., 2012; Lassman
et al., 2010) has allowed the exploration of BOLD signal responsesthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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areas involved in the regulation of food intake such as the brainstem
and hypothalamus.
It is well established that the presence of glucose in the small intes-
tinal lumen is associatedwith decreased hunger, increased fullness, and
decreased energy intake at a subsequent meal (Cook et al., 1997; Lavin
et al., 1996; Pilichiewicz et al., 2007), but the brain centres and trans-
duction mechanisms underlying these effects are poorly deﬁned in
humans. Animal studies have identiﬁed the hypothalamus as a critical
region for the regulation of energy balance (Brown and Melzack,
1969; Grossman, 1975), and in man, a number of fMRI studies have re-
ported that oral glucose decreases hypothalamic BOLD signal, relative to
water (Liu et al., 2000; Smeets et al., 2005a, 2005b, 2007; Vidarsdottir
et al., 2007). However, these studies did not investigate the responses
of other sub-cortical brain regions to glucose, and the movement of
the head during consumption of oral meals induced imaging arte-
facts that precluded evaluation of the early responses. In particular,
detailed imaging of the human brainstem has not been reported
and is critical as it is the ﬁrst relay point responsible for integrating
neural signals transmitted from the upper gut via vagal afferent
neurons.
The mechanism by which the presence of glucose in the gut is
signalled to the human central nervous system is likely to involve
an interaction between direct responses to elevated circulating glu-
cose concentrations (Levin et al., 2004), and indirect responses via
glucose sensitive neural (e.g. vagal), or endocrine signalling path-
ways (e.g. insulin (Liu et al., 2000; Smeets et al., 2005b) and/or gut
derived peptides, such as cholecystokinin (CCK) (Lassman et al.,
2010; Little et al., 2010) and glucagon-like peptide-1 (GLP-1)
(Pannacciulli et al., 2007)). Recent studies have indicated that
signals arising from the gastrointestinal tract are likely to play an
important role in mediating the hypothalamic response to glucose.
For example, the effect of glucose on hypothalamic BOLD signal
has been reported to be greater when administered orally compared
to intravenously (Smeets et al., 2007). The hypothalamic response
has also been related to fasting insulin concentrations (Liu et al.,
2000; Matsuda et al., 1999), and additionally a relationship has
been found between postprandial plasma GLP-1 concentrations
and increases in BOLD signal in the left dorsolateral prefrontal cor-
tex and the hypothalamus, following ingestion of a liquid meal
(Pannacciulli et al., 2007). However, in these previous studies,
whole brain responses, and time courses of the response could not
be evaluated.
Using physMRI to investigate whole brain responses, we have previ-
ously shown that intragastrically administered lipid (the fatty acid,
lauric acid (C12)) increases BOLD signal in key human brain areas, in-
cluding the brainstem and hypothalamus (Lassman et al., 2010). These
activations were abolished by the administration of the CCK1 receptor
antagonist, dexloxiglumide (Lassman et al., 2010), and modulated by
ghrelin (Jones et al., 2012).
We, therefore, decided to apply the same imaging technique to
identify and deﬁne the brain regions responsive to glucose. Like
lipid, glucose ingestion is known to slow gastric emptying (Hunt
and Knox, 1968), and to induce gallbladder contraction (de Boer
et al., 1993). In addition, dexloxiglumide attenuates the inhibitory
effects of glucose on gastric emptying (Fried et al., 1991; Little et al.,
2010), suggesting that CCK is also involved in this, and possiblymediat-
ing the gut-to-brain signalling response to glucose. Therefore, the CNS
response to different macronutrients may be predicted to have signiﬁ-
cant overlaps.
This study therefore had two aims: ﬁrst, to determine whether
intragastric glucose would induce changes in BOLD signal in the
same nutrient-sensitive regions, robustly observed in response to
lipid, namely the brainstem and hypothalamus, and second, to deter-
mine whether any effects of glucose observed in the CNS were also
CCK1 receptor-dependent.Methods
Subjects
12 healthy volunteers (7 males, mean (SEM) age: 38 (3.4)
(range: 23–60) years) with a non-obese body mass index (BMI: 24
(1) (range: 19.7–28.9) kg/m2) were recruited from the staff and local
population of Salford Royal NHS Foundation Trust. Exclusion criteria
comprised: presence of any gastrointestinal, endocrine or metabolic
disease; consumption of medications that may affect gastrointestinal
function, sensation or appetite; metallic implants or objects (e.g. hear-
ing aid, pacemaker), and consumption of greater than 20 g of alcohol
or 10 cigarettes/day. All were instructed to abstain from alcohol and
vigorous physical activity for 24 h prior to the study. In both the gastric
emptying and the fMRI study arms, participants were blinded both to
the nature of the intragastric infusions, and to the drug, and studies
were performed in a randomised order. Randomisation was performed
using a random number generator. Participants provided informed
written consent. The study was approved by the Salford and Trafford
Research Ethics Committee, and was carried out in accordance with
the Code of Ethics of the World Medical Association (Declaration of
Helsinki) and the standards established by the author's ethics commit-
tee and granting agency. All participants provided informed, written
consent after the nature of the experimental procedures provided in
writing.
Materials
D-Glucose was purchased from Sigma-Aldrich (Gillingham,
England). The CCK1 receptor antagonist, dexloxiglumide (300 mg
tablets), and matched placebo tablets were supplied at no cost by
Rottapharm (Monza, Italy) as a scientiﬁc collaboration.
Gastric emptying protocol
As the medulla houses the sensory and motor nuclei responsible for
relaying vago-vagal enteric circuits, as well as signalling to higher cen-
tres, we used the measurement of changes in gastric emptying induced
by glucose as a convenient proxy measure to identify a dose of glucose
that would have effects on brainstem BOLD response (Little et al.,
2010). Participants arrived at the laboratory at 09:00 h after an over-
night fast from 22:00 h and orally ingested either 600 mg of
dexloxiglumide (1 occasion), or matched placebo (2 occasions), tab-
lets. Previous studies in our laboratory have demonstrated that this
dose effectively blocks the effects of lipid (lauric acid (C12)) (Lal
et al., 2004) and glucose (Little et al., 2010) on gastric emptying,
and the effect of lipid on BOLD signal in the brainstem and hypothal-
amus (Lassman et al., 2010). One hour later, a nasogastric feeding
tube was positioned, with its distal tip in the stomach. Gastric deliv-
ery was employed to eliminate sensory or hedonic effects of oral
sweet tasting, and for the MRI studies, movement artefacts during
drinking and swallowing. A basal, end-expiratory, breath sample
was collected; followingwhich participants received a bolus intragastric
infusion of 250 ml glucose (45 g, 180 kcal, 1000 mOsmol) or 250 ml of
water (volumetric control). Each meal was labelled with 100 mg 13C-
sodium acetate, used as a marker for gastric emptying (CK Gas Products
Ltd., UK). For the assessment of gastric emptying rate, end-expiratory
breath samples were collected at 5 minute intervals over a period of
45 min (Little et al., 2009, 2010). On each occasion, the subject exhaled
through amouth-piece to collect an end-expiratory breath sample into a
100ml foil bag, whichwas then sealedwith a plastic stopper, and stored
for later analysis.
Breath samples were analysed by non-dispersive infrared spectros-
copy (IRIS, Wagner Analysen Technik, Bremen, Germany). This enabled
evaluation of the isotopic composition of carbon in the expired carbon
dioxide (CO2) by determination of the ratio of 13C:12C in the sample
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metabolized after it is emptied from the stomach, hence the rate of ap-
pearance of 13CO2 in the systemic circulation closely corresponds to the
rate of GE (Sanaka et al., 2006).
physMRI protocol
12 participants were studied on three separate occasions at 08:30 h
following anovernight fast from22:00h, to evaluate the spatiotemporal
pattern of brain activation in response to intragastric infusion of: (i) glu-
cose (250 ml, 1000 mOsmol (45 g glucose, 180 kcal)) following two
placebo tablets, (ii) glucose (250 ml, 1000 mOsmol) following the
CCK1 receptor antagonist, dexloxiglumide (600 mg (two 300 mg
tablets)) (glucose + dex), and (iii) 0.9% saline (control) following two
placebo tablets. The dexloxiglumide (condition ii), or matched placebo,
tablets (conditions i and iii), were orally ingestedwith 100ml ofwater 1
h prior to the commencement of the intragastric infusion. All conditions
were matched exactly to our previous studies (Jones et al., 2012;
Lassman et al., 2010) to enable direct comparison between the
glucose- and lipid-induced nutrient matrices. In the study design we
purposefully omitted a saline+dex control arm sincewe had previous-
ly demonstrated, under the same study conditions (i.e. after an over-
night fast and with identical imaging parameters), that there was no
effect of dexloxiglumide in the absence of nutrient (i.e. during
intragastric saline infusion) on BOLD signal across the whole brain
(Lassman et al., 2010). Furthermore, dexloxiglumide has no effect on
the gastric emptying of water/saline (Little et al., 2010). Due to the
large number of statistical comparisons to be performed, which do not
require the placebo/placebo condition, andmindful of burden on exper-
imental subjects, we considered that repeating this was unjustiﬁed.
Thirty minutes prior to scanning, participants were intubatedwith a
nasogastric feeding tube and an intravenous cannula was positioned in
an antecubital vein to enable repeated blood sampling. Participants
were then positioned in the scanner (3.0 T Philips Achieva MR System,
Magnetic Resonance Imaging Facility (MRIF), Salford Royal NHS Foun-
dation Trust) and images of the gallbladder acquired. Immediately
following this, participants were repositioned in the scanner for the
30 minute fMRI scan. After a baseline period of 4 min, the intragastric
infusion (glucose or saline) was administered as a bolus, using a syringe
via thenasogastric tube, over a period of 1min. Subjective ratings of full-
ness, hunger and nausea were recorded every 5 min throughout the
scan. Venous blood samples were taken to assess blood glucose, and
plasma insulin, CCK and GLP-1 concentrations at the start of the scan
protocol (t=0 min), and then at t=5, 10, 15, 20, and 25min following
the intragastric infusion. After the fMRI scan, a second gallbladder
image was acquired. On the ﬁrst visit, participants were positioned in
the scanner an additional 10 min before the commencement of the
scanning protocol to enable a high-resolution structural scan to be per-
formed to more accurately normalise each individual's brain anatomy.
Gallbladder MR acquisition and volume measurement
Gallbladder volume, which is a classical in vivo bioassay for CCK
activity, was determined to evaluate the functional signiﬁcance of the
CCK response to the glucose test meals and as a positive control for
CCK1 receptor blockade by dexloxiglumide (Lilja et al., 1982). Complete
blockade of gallbladder contraction demonstrates effective CCK1 recep-
tor antagonism. Volumeswere determined from single-shot, T2weight-
ed axial, coronal and sagittal 3 T anatomical MR images of the upper
abdomen obtained at the beginning and end of each study using a
SENSE torso coil triggered by respiration. Gallbladder volume was
estimated using the ellipsoid method, whereby volume = length ×
depth × width × 0.523 (where π/6 = 0.523, depth = maximum
antero-posterior diameter and width= maximum lateral diameter)
(Dodds et al., 1985; Lassman et al., 2010).Sensation scores
Subjects were asked to indicate their sensations of hunger, fullness
and nausea on a 10 point scale, every 5 min during each scan. The sub-
ject rated each sensation by moving a pointer along the scale, via a re-
sponse box held in their right hand (Lassman et al., 2010).
Blood glucose, plasma insulin, CCK and GLP-1 measurements
Venous blood samples (10 ml) were collected into ice-chilled lithi-
um heparin-treated tubes containing 400 kIU aprotinin per ml blood
(Trasylol; Bayer Ltd., Berkshire, UK). Plasma was separated by centrifu-
gation at 3000 rpm for 10min at 4 °Cwithin 1 h of collection, and stored
at−70 °C until assayed.
Venous blood glucose concentrations (mmol/l) were determined at
the time of collection by the glucose oxidase method using a portable
glucose meter (Medisense Optium Xceed, Abbott, Alameda CA USA).
The accuracy of this method has been conﬁrmed using the hexokinase
technique (Horowitz et al., 1991).
Plasma insulin concentrationswere determined using the ALPCO In-
sulin ELISA kit (ALPCO, Product number: 80-INSHU-E01.1, Salem, NH,
USA). The sensitivity of the assay is 0.399 uIU/ml. The intra-assay coef-
ﬁcients of variability (CVs) were 5.1–10.3%, and the inter-assay CVs
were 6.7–16.6%.
Plasma GLP-1 concentrations were determined using the ALPCO
GLP-1 (7–36) and GLP-1 (9–36) ELISA kit (ALPCO, Product number:
43-GPTHU-E01, Salem, NH, USA). The assay has 0.01% cross-reactivity
with GLP-1 and glucagon. The sensitivity of this assay is 0.06 pmol/l.
The intra-assay CVs were 3.7–4.7%, and the inter-assay CVs were 6.2–
9.5%.
Plasma CCK concentrations were determined using the ALPCO
EURIA-CCK radioimmunoassay kit (ALPCO, Product number: 13-
RB302). The assay has 0.5% cross-reactivity with gastrin-17 sulphated,
and b0.01% with gastrin-17 non-sulphated. The sensitivity of the
assay is 0.3 pmol/l. The intra-assay CVs were 2–5.5%, and the inter-
assay CVs were 4.1–13.7%.
MRI acquisition
fMRI brain volumes were acquired at 5 second intervals for 30 min
using a multi-slice, single-shot EPI sequence to achieve whole brain
coverage: 40 axial slices, TR/TE = 5000/35 ms, voxel size = 1.8 ×
1.8 × 3.5 mm, ﬂip angle = 79°, SENSE acceleration factor = 1.8,
matrix = 128 × 128, FOV = 240 × 240 mm. Daily quality assurance
was carried out to ensure a consistent high signal-to-ghost ratio
using an automated quality control procedure. A SENSE 8 channel
head coil was used for radio frequency transmission and reception.
MRI image analysis
The fMRI data were analysed using Statistical Parametric Mapping
(SPM8, www.ﬁl.ion.ucl.ac.uk/spm). Images were realigned, spatially
normalised and smoothed to facilitate inter-subject averaging. The
limits on head movement for inclusion were: 2 mm for x- and y-
translation and 4 mm for z-translation, both per volume and across
the whole scan, and 3° for yaw and 1.5° for roll and pitch, again per vol-
ume and across the whole scan.
First-level analysis was performed, using the p-block ph/physMRI
analysis technique (Jones et al., 2012; Lassman et al., 2010; McKie
et al., 2005, 2011), on each subject for each study condition in the fol-
lowing ways: the pre- and post-infusion scans were split into two min-
ute time-bins. The post-infusion scans were divided into 13 consecutive
2 minute time bins (T1–13) and the 24 scans from the 2 min immedi-
ately prior to the glucose/saline infusion formed the baseline time bin
(T0). In each subject and condition, the signal averages for the 13
post-infusion time bins (T1–T13) were separately compared to the
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framework. This resulted in 13 ﬁrst level images corresponding to the
BOLD signal change from baseline in each successive post-infusion
time bin for each subject and condition. The realignment parameters
for each session were included as regressors of no interest to correct
for motion. Scanner drift was modelled using the scaling option for
global normalisation in SPM. Contrast maps across time for glucose vs.
saline and glucose vs. glucose + dex were calculated for each subject.
To determine whether statistically signiﬁcant increments in the
BOLD signal change from baseline across subjects occurred over time,
two repeated-measures ANOVAs were used, one for the glucose vs.
saline comparison and the other for the glucose vs. glucose+ dex com-
parison, at a cluster-level statistical inference of p(False Discovery Rate;
FDRc) b 0.05 at a height threshold of p = 0.005.
Correlations were performed to determine relationships between
changes in BOLD signal with blood glucose, plasma GLP-1 and insulin
concentrations, and the subjective ratings of nausea, hunger and
fullness. These were performed using the average values per subject
(area under the curve (AUC) and across time) for each signiﬁcant cluster
extracted from the glucose vs. saline and glucose + dex vs. saline com-
parisons. For the AUC correlations, all time bin BOLD signal change con-
trastswere averaged per cluster and compared to the baseline corrected
AUC blood concentrations for each individual. For the correlations with
time, each cluster's average BOLD signal at ﬁve time bins (T+5, T+ 10,
T + 15, T + 20 and T + 25 min) was calculated and correlated to the
each subject's blood concentration measures at the same time points.
This resulted in a correlation coefﬁcient, r, for each subject. Each
subject's r-values were then entered into a one-sample t-test. All corre-
lations are reported at a False Discovery Rate level (pFDR b 0.05)
correcting for the number of cluster signiﬁcant regions being tested.
Analysis of gastric emptying, blood glucose and GI hormone concentrations
and appetite perceptions
Gastric emptying, blood glucose, plasma CCK, GLP-1 and insulin
concentrations are displayed as raw data. VAS scores were analysed
as change from baseline values. Areas under the curve were calculat-
ed for gastric emptying and blood glucose, CCK, GLP-1 and insulin
concentrations using the trapezoidal rule. These data were analysed
using repeated measures ANOVAs with treatment, and time (or for
the AUC data, treatment) as factors. If ANOVAs revealed statistical
signiﬁcance, post-hoc paired comparisons, corrected for multiple
comparisons using Bonferroni's correction, were performed. Statisti-
cal analysis was performed using SPSS Version 17.0. Data are pre-
sented as means (SEM).
Results
The study was well tolerated by all participants. Due to difﬁculty
obtaining blood samples from 2 of the participants while in the scanner,Fig. 1. (A) Gastric emptying (n = 3/12) and (B) change in gallbladder volume (n = 12) foll
(600 mg) or saline/water control. Data are mean (SEM). *glucose vs. water/saline, ^glucose +complete data sets for glucose, insulin, CCK andGLP-1 are available from
only 10 participants. Three participants self-reported smoking ≤ three
cigarettes/day. There were no apparent differences in gastric emptying,
BOLD response or gut peptide secretion between the smokers and non-
smokers, but this could not be formally evaluated due to the small
numbers.
Gastric emptying
As in our previous study (Little et al., 2010), we demonstrated an
effect of treatment on gastric emptying (p= 0.003). Intragastric glu-
cose slowed gastric emptying when compared with water (p =
0.017), and dexloxiglumide abolished this glucose-induced inhibition
(p = 0.031), with no difference between the emptying of water and
glucose+dex. The slower gastric emptying observed after glucose con-
sumption is therefore CCK1-receptor dependent (Fig. 1A).
Gallbladder volumes
There was an effect of intragastric glucose on gallbladder volume
(Fig. 1B). Glucose decreased the volume of the gallbladder (p =
0.014) when compared with saline. As with gastric emptying, the
effect of glucose was attenuated by dexloxiglumide pre-treatment
(p = 0.008). This provides evidence of fully effective CCK1 receptor
blockade by dexloxiglumide.
Areas of glucose-induced BOLD signal change
Results of the one-way ANOVAs investigating the differences in
BOLD signal responses over time following intragastric glucose (relative
to saline) are presented in Table 1 and Figs. 2 and 4. A signiﬁcant effect
of timewas observed in sections of the brainstem (Figs. 4A, B, C) and hy-
pothalamus (Fig. 4D) (regions previously reported to show a positive
BOLD response between lipid and saline (Jones et al., 2012; Lassman
et al., 2010)), as well as the cerebellum, right fusiform and lingual
gyri, insula/putamen, left parahippocampal gyrus, right middle tempo-
ral and thalamic regions. Investigation of the average time courses for
these signiﬁcant clusters highlighted that the effect of time was
generally driven by an initial increase in BOLD signal followed by
sharp decrease at 5 min (Fig. 4).
Effect of dexloxiglumide on areas of BOLD signal change
Dexloxiglumide pre-treatment signiﬁcantly modulated the BOLD
signal response over time in the regions summarised in Table 2 and
Fig. 3. Investigation of the average time courses for the signiﬁcant clus-
ters highlighted partial blockade of the effect of glucose to decrease
BOLD signal in the hypothalamus (Fig. 4D). The supplementary motor
area is of particular interest as this was the only region to show a posi-
tive BOLD response to glucose ingestion (glucose vs. saline) over time,owing intragastric glucose (1000 mOsmol), glucose (1000 mOsmol) + dexloxiglumide
dex vs. glucose, p b 0.05.
Table 1
Signiﬁcant central nervous systemclusters exhibiting effect of time between glucose and saline infusions: p(FDRc b 0.05) at p = 0.005. TD— TalairachDaemon; pFDRc— cluster size False
Discovery Rate p-value; CoM — centre of mass; x,y,z {mm} —Montreal Neurological Institute (MNI) coordinates from anterior commissure origin; wrt —with respect to.
Cluster-level statistics (Glucose vs saline) ∗ time CoM Glucose vs saline correlation
wrt time
Glucose + dex vs saline
correlation wrt time
Blood glucose Insulin Blood glucose Insulin
Size at p b 0.005 pFDRc TD lobes & hypothalamus x,y,z {mm} pFDR pFDR
61 0.045 Brainstem–medulla L + R 1 −43 −47 0.034 0.055 ns ns
77 0.023 Brainstem–pons L + R 3 −39 −36 0.030 0.055 ns ns
121 0.004 Brainstem–midbrain L + R 2 −34 −19 0.013 0.026 ns ns
104 0.007 Hypothalamus L + R 2 −3 −12 0.007 0.004 ns ns
111 0.006 Cerebellum–anterior L + R −2 −42 −33 0.012 0.019 ns ns
357 b0.001 Cerebellum L −23 −56 −41 0.012 0.019 0.062 0.042
177 b0.001 Cerebellum R 17 −52 −22 0.026 0.029 0.070 0.037
95 0.011 Fusiform_R 30 −73 −9 0.012 0.017 0.026 0.005
76 0.024 Lingual_R 10 −71 −7 ns ns 0.050 0.009
42 0.099 Insula_L/putamen_L −27 −15 7 ns ns ns ns
68 0.033 Insula_R/putamen_R 35 −17 2 ns ns ns ns
71 0.030 Parahippocampal_L −17 −3 −22 ns ns ns 0.049
59 0.049 Temporal_Mid_R 53 −45 5 ns ns ns ns
60 0.047 Thalamus_L −17 −28 3 0.058 ns ns ns
47 0.080 Thalamus_R 11 −26 1 0.029 ns ns ns
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of the average time course in the other brain regions in Table 2 showed
that effect of time was driven in two separate ways: 1) for the cerebel-
lum, left caudate, left and right cuneus, and left lingual gyrus, the effect
of time was driven by the BOLD response for glucose + dex vs. saline
being further reduced relative to glucose vs. saline, and 2) for the
other regions the effect of time was driven by the initial glucose-
induced increase in BOLD signal and subsequent sharp decrease at
5 min being abolished by dexloxiglumide pretreatment.Fig. 2. Brain images showing areas exhibiting signiﬁcant effect of time (pFDRc b 0.05 at p b 0.00
brain, hypo: hypothalamus, thal: thalamus, ling: lingual gyrus, phg: parahippocampal gyrus, pTime course of changes in BOLD signal
Therewere signiﬁcant correlations between the time course of BOLD
signal changes with the time course of changes in circulating blood glu-
cose and insulin concentrations in all of the brainstem, hypothalamic,
cerebellar, fusiform and thalamic regions responding to glucose
(Table 1). This temporal correlation was removed by pretreatment
with dexloxiglumide in all of these regions, apart from the lateral cere-
bellum and the right occipital cortex (fusiform and lingual gyrus). A5) for glucose versus saline contrast. cb: cerebellum, pons/med: pons/medulla, mid: mid-
ut: putamen, ins: insula, mtg: middle temporal gyrus.
Table 2
Signiﬁcant central nervous system clusters exhibiting effect of time between glucose infusion and glucose infusion following pretreatment with dexloxiglumide p(FDRc b 0.05) at
p = 0.005. TD— Talairach Daemon; qFDRc— cluster size False Discovery Rate q-value; CoM— centre of mass; x,y,z {mm}—Montreal Neurological Institute (MNI) coordinates from an-
terior commissure origin; wrt —with respect to.
Cluster-level statistics (Glucose vs glucose + dex)*time CoM Glucose vs saline
correlation wrt time
Gluc + dex vs saline correlation
wrt time
Blood glucose Insulin Blood glucose Insulin glp-1
Size at p b 0.005 pFDRc TD lobes & hypothalamus x,y,z {mm} pFDR pFDR
71 0.031 Hypothalamus L + R 4 −1 −13 0.005 0.004 ns ns ns
1027 0.000 Cerebellum L + R −2 −53 −23 0.031 0.048 ns 0.026 0.045
93 0.014 Caudate_L −14 21 0 ns ns ns ns ns
119 0.005 Cingulum_Mid_L −10 −27 37 ns ns ns ns ns
62 0.043 Cuneus_L −14 −76 31 ns ns ns 0.024 0.022
150 0.002 Cuneus_R 13 −78 27 ns ns ns 0.035 0.016
119 0.005 Insula_L/Putamen_L −39 −18 8 ns ns ns ns ns
89 0.016 Insula_R/Putamen_R 22 11 −7 0.003 0.011 ns ns ns
184 b0.001 Lingual_L −15 −68 −7 0.030 0.038 ns 0.035 0.030
80 0.022 Occipital_Inf_R 36 −76 −8 ns ns ns ns ns
104 0.009 Parahippocampal_L −16 −37 −1 ns ns ns ns ns
72 0.030 Parietal_Sup_L −18 −59 45 ns ns ns ns ns
65 0.039 Parietal_Sup_R 16 −65 52 ns ns ns ns ns
71 0.031 Precuneus_L −13 −52 17 0.029 0.045 ns ns ns
127 0.004 Precuneus_R 14 −68 46 ns ns ns ns ns
63 0.042 Supp_Motor_Area_L + R 7 15 53 ns ns ns ns ns
130 0.004 Temporal_Mid_R 52 −47 4 ns ns ns ns ns
63 0.042 Thalamus_L −17 −27 5 ns ns ns ns ns
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with insulin was also observed in the left parahippocampal region.
There were no signiﬁcant correlations between BOLD signal changes
with the AUC of blood glucose, GI hormones or subjective appetitemea-
sures. There were no signiﬁcant temporal correlations between BOLD
signal changes with GLP-1, or any of the subjective appetite measures.
With respect to clusters that showed a signiﬁcant modulation of the
glucose-induced BOLD signal by dexloxiglumide, there were correla-
tions between the time course of the BOLD signal change with the
time course of blood glucose and insulin concentrations in thehypothal-
amus, cerebellum, right putamen, left lingual gyrus and left precuneus
(Table 2). Therewere no temporal correlations between the time course
for blood glucose and the time course for the glucose + dex vs. saline
BOLD signal in any region, however, there were temporal correlations
observed with insulin and GLP-1 in the cerebellum, bilateral cuneus
and left lingual gyrus i.e. the clusters that showed an the effect of time
driven by the BOLD response for glucose + dex vs. saline being further
reduced in comparison to glucose vs. saline. Interestingly, in the sup-
plementary motor area, where BOLD signal increased in response to
glucose (and where the effect was reversed by dexloxiglumide),
there was no temporal correlation with circulating blood glucose,Fig. 3. Brain images showing areas exhibiting signiﬁcant effect of time (pFDRc b 0.05 at p b 0.0
caudate, mc: motor cortex (SMA).insulin or GLP-1 concentrations (Table 2). There were no signiﬁcant
correlations between BOLD signal changes and the AUC of blood glu-
cose, hormones or subjective appetite measures. There were no sig-
niﬁcant temporal correlations with BOLD for any of the subjective
appetite measures.
Blood glucose, plasma insulin, CCK and GLP-1 concentrations
Glucose
There was an effect of treatment on blood glucose concentrations
(p = 0.002). Both glucose (p = 0.001) and glucose + dex (p =
0.009) increased blood glucose concentrations when compared
with saline, with no difference between glucose and glucose + dex
(p = 1.000) (Fig. 5A).
Insulin
There was an effect of treatment on the AUC for serum insulin con-
centrations (p b 0.001). Both glucose (p = 0.003) and glucose + dex
(p = 0.001) increased serum insulin concentrations when compared
with saline. There was a treatment ∗ time interaction (p b 0.001). Insu-
lin concentrations were greater for glucose and glucose+ dex between05) for glucose versus glucose + dex contrast. hypo: hypothalamus, put: putamen, caud:
Fig. 4. Changes in blood-oxygenation-level-dependent (BOLD) signal over time in the medulla (A), pons (B), midbrain (C), and hypothalamus (D), and motor cortex (E), following bolus
intragastric glucose (1000 mOsmol) and glucose + dex, relative to saline.
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when compared with glucose at t = 25 min (Fig. 5B).
CCK
There was an effect of treatment on the AUC for plasma CCK concen-
trations (p= 0.002). CCKwas increased following glucose+ dexwhen
compared with glucose (p = 0.005) and saline (p = 0.007), with no
differences between glucose and saline (p = 0.395) (Fig. 5C).
GLP-1
There was an effect of treatment on the AUC for plasma GLP-1 con-
centrations (p= 0.001) (Fig. 5D). Glucose increased plasmaGLP-1 con-
centrationswhen comparedwith saline (p= 0.047), with no difference
between glucose and glucose + dex, or glucose + dex and saline.
Perceptions of hunger, fullness and nausea
There were no differences in baseline ratings, nor any effect of any
treatment, on perceptions of nausea (Fig. 6A) or hunger (Fig. 6B).
There was an effect of treatment for fullness scores (p= 0.05). Glucose
increased fullness when compared with saline (p = 0.009), with no
differences between saline and glucose + dex (Fig. 6C).Changes in fullness were not correlated to circulating levels of glu-
cose, CCK, GLP-1 or insulin. Ratings of hunger were weakly related to
plasma insulin (R = 0.36, P = 0.052), but not CCK, glucose or GLP-1,
concentrations.Discussion
The development of whole brain fMRI applied to intragastric infu-
sion of nutrients (physiological MRI; physMRI) has provided an entirely
new means to understand the gut-to-brain signalling mechanisms reg-
ulating gastrointestinal function, appetite and food intake in humans
(Jones et al., 2012; Lassman et al., 2010). We have now, for the ﬁrst
time, demonstrated thewhole brain responses to glucose when admin-
istered directly into the stomach to avoid the confounding effects of
sight, taste or smell, and overcoming the technical issues associated
with movement during swallowing. In themedulla, pons, andmidbrain
regions of the brainstem and in the hypothalamus (and other areas
outlined in Table 1) glucose, compared to the saline, decreased the
BOLD signal at 5 min, after a small initial increase. The brainstem and
hypothalamic regions have previously been identiﬁed to respond to
intragastric lipid, using identical methods (Jones et al., 2012; Lassman
et al., 2010). However, in response to glucose, the decrease in BOLD
Fig. 5. Blood glucose (A) and plasma insulin (B), cholecystokinin (CCK) (C) and glucagon-like peptide-1 (GLP-1) (D) concentrations following bolus intragastric glucose (1000 mOsmol),
glucose + dexloxiglumide, or saline (0.9%). *glucose vs. saline, p b 0.01, ^glucose + dex vs. saline, p b 0.001, #glucose vs. glucose + dex, p b 0.05, n = 10.
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plasma insulin concentrations.
Since CCK clearlymediated gastric and gall bladder emptying follow-
ing intragastric glucose, the role of CCK in the CNS response to
intragastric infusion of glucose was investigated using a pretreatment
with dexloxiglumide (a CCK1 receptor antagonist). Investigation of the
interaction between glucose and glucose + dex over time revealed
several interesting results. There was a partial blocking of the effect of
glucose to decrease BOLD signal in thehypothalamus by dexloxiglumide.
Dexloxiglumide furthermore abolished the effect of glucose in themotor
cortex, the only region to showaBOLD signal increase in response to glu-
cose. In the cerebellum, left caudate, bilateral cuneus and left lingual
gyrus, dexloxiglumide pre-treatment further reduced the glucose BOLD
response. Interestingly, there was a signiﬁcant temporal correlation
with insulin and GLP-1 in all these regions apart from the left caudate.
For the remaining regions dexloxiglumide changed the temporal
characteristics of the glucose response by abolishing the initial in-
crease in BOLD signal as observed for glucose vs. saline.
With regard to the areas showing decreased BOLD signal, our ob-
servations conﬁrm previous reports of a decrease in BOLD signal
within the hypothalamus following either oral or intravenous glu-
cose in humans (Liu et al., 2000; Matsuda et al., 1999; Smeets et al.,
2005a, 2005b, 2007; Vidarsdottir et al., 2007), and rats (Chen et al.,
2007; Tsurugizawa et al., 2008), and for the ﬁrst time deﬁne the
brainstem response to the presence of glucose in the GI tract in
humans. In seeking to explore candidate pathways for these effects
of glucose to decrease BOLD signal in the CNS regions outlined in
Table 1, our dexloxiglumide data indicate that, unlike the response
to lipid (Lassman et al., 2010), the response to glucose in these re-
gions is not solely dependent on the activation of CCK1 receptors
on vagal afferents. Even though we demonstrated that glucose does
activate processes known to be CCK-dependent (i.e. dexloxiglumide
reversible gallbladder contraction and slowing of gastric emptying
(Fried et al., 1991; Little et al., 2010; Moran et al., 1997)), there
was no signiﬁcant effect of dexloxiglumide on BOLD signal reduction
in these regions. This suggests that although glucose is likely to haveactivated a subset of neurons via the CCK1 receptor (as demonstrated
by the dexloxiglumide sensitive increase in BOLD signal in cortical
areas and possibly the small initial rise in BOLD signal observed
prior to the decrease in the brainstem), there was also an additional,
perhaps more direct, inhibitory action of circulating glucose and in-
sulin, which may have occurred at the level of peripheral vagal affer-
ents, and/or the brainstem and hypothalamus. This is supported by
the observation that in rats, BOLD signal responses in the lateral hy-
pothalamus, as well as other brain regions, to post-oral glucose were
the same in both intact and vagotomised rats, whereas BOLD signal
responses to glutamine were attenuated in vagotomised rats. This
suggests that speciﬁc responses occur to different types of nutrients,
with vagal activity being critical for the sensing of glutamine and
lipid (Lassman et al., 2010), and humoral factors, such as insulin, as
well as changes in circulating glucose levels, being important for glu-
cose detection (Tsurugizawa et al., 2009). To this effect a direct compar-
ison of our independent studies using intragastric lipid and glucose has
been provided as supplementary data.
It is recognised that elevated glucose levels can directly inﬂuence the
activity of speciﬁc glucose-sensing neurons in hypothalamic and
brainstem regions (Levin et al., 2004), and that there are subsets of neu-
rons in which elevated glucose levels are either excitatory or inhibitory
(Grabauskas et al., 2010; Levin et al., 2004). In addition, elevated blood
glucose may have been signalling to the brain via activation (excitation
or inhibition) of peripheral glucose-sensing neurons in the nodose gan-
glia (Grabauskas et al., 2010). Animal studies strongly indicate that
vago-vagal pathways play an important role in the regulation of gastro-
intestinal motility (Zhou et al., 2008) and eating behaviour (Grabauskas
et al., 2008) in response to acute changes in blood glucose levels. Addi-
tionally, acute increases in glucose levels modulate synaptic connec-
tions between vagal afferent nerve terminals and neurons in the
nucleus tractus solitarius (Wan and Browning, 2008). However, while
one study has demonstrated an effect of intravenous glucose on BOLD
signal in the hypothalamus (Smeets et al., 2007), this effectwas not rep-
licated by others, despite inducing comparable increases in blood glu-
cose concentrations (Purnell et al., 2011). A number of studies have
Fig. 6. Effects of saline, glucose and glucose + dexloxiglumide on perceptions of nausea
(A), hunger (B) and fullness (C). There were no differences in baseline ratings, nor any
effect of any treatment, on perceptions of nausea or hunger. There was an effect of treat-
ment for fullness scores (p = 0.05). Glucose increased fullness when compared with
saline (p = 0.009), with no differences between saline and glucose + dex. *P b 0.05 glu-
cose vs. saline.
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glucose-induced changes in BOLD signal in the hypothalamus (Smeets
et al., 2005a, 2007). Here, we have demonstrated a strong correlation
between the timing of changes in blood glucose and plasma insulin
levels, and the decrease in BOLD signal, suggesting that changes in circu-
lating glucose and insulin concentrations are likely to be key mediators
of the central response to glucose, rather than direct vagal afferent
signalling from the gut.
While we did demonstrate that dexloxiglumide accelerated gastric
emptying of glucose, this was not of a sufﬁcient magnitude tomodulate
circulating glucose or insulin levels, and indeed, in the CNS regions in
which we observed a signiﬁcant relationship with glucose and insulin
(i.e. those regions in which BOLD signal decreased), there was no differ-
ence in effect between glucose and glucose + dex conditions. Hence,
gastric emptying rate is unlikely to be a major determinant of the CNS
response reported here.
It appears from our data that the onset of the BOLD signal rise in the
motor cortex was rapid, occurring within 5 min post-infusion and be-
fore any measurable elevation of plasma glucose. Further analysis of
the direct comparison between glucose and lipid BOLD responses,
using a two-way repeated measures ANOVA with nutrient (vs. saline)
as a between subject factor and time as a within subject factor,highlighted the spatial similarity and temporal interaction between glu-
cose and lipid (Jones et al., 2012; Lassman et al., 2010) related changes
in BOLD signal (Supplementary material). The data included in this
comparison were collected in parallel on the same scanner with the
same imaging parameters during the same time period. The motor cor-
tex was not signiﬁcant in this analysis due to a lack of direct overlap in
themotor cortex for glucose and lipid however the time course for lipid
from themotor cortex in Fig. 3D from Lassman et al., 2010 and in Fig. 4A
in this paper are very similar (Supplementary Fig. 1A). Previous studies
have also demonstrated that cortical areas (including themotor cortex)
display an increase in BOLD signal during intravenous glucose (Purnell
et al., 2011). That this responsewas blocked by dexloxiglumide suggests
that the early changes in BOLD signal were mediated by a peripheral
vagal CCK1 receptor-dependent pathway. This is supported by a recent
study that identiﬁed a positive relationship between changes in BOLD
signal in the thalamus, amygdala, caudate, insula and orbitofrontal
cortex with changes in plasma CCK concentrations following oral
glucose ingestion (Li et al., 2012). The current study however went
beyond pure observation and utilised the CCK1 receptor antagonist
dexloxiglumide, which we have previously shown to abolish the effect
of lipid. Therefore this correlation cannot be causal: the fact that BOLD
changes are in opposing directions in our studywouldmake an identical
signalling molecule driving both rather implausible. We validated that
CCK activity was fully blockaded in our study by demonstrating the ab-
olition of glucose-induced gallbladder contraction:measuring peripher-
al blood levels of CCK is clearly a poor assay of biological activity in this
system, sincemuch of the effects of CCK occur at a paracrine levelwithin
the gut. Where possible, physiology is better explored by using inter-
ventions such as receptor blockade.
It therefore appears that the effects of intestinal glucose are mediat-
ed by at least two nutrient sensing pathways in the CNS, both of which
may modify appetite, eating behaviour and digestive function either
directly (e.g. central detection of circulating insulin/glucose concentra-
tions) or indirectly (e.g. activation of vagal afferents via gut peptides).
It should also be noted that intragastric infusion, while having bene-
ﬁts of ensuring consistent rate of nutrient delivery to the intestine and
allowing a pure focus on gut-to-brain signals, does not entirely reﬂect
normal meal ingestion due to the exclusion of oral and cephalic phases.
For example, our analyses did not reveal relationships between BOLD
signal changes with appetite perceptions. These analyses are likely to
be underpowered since we were unable to collect blood from two par-
ticipantswhile theywere in the scanner. Additionally, subjective ratings
of hunger and fullness in several subjects showed no change from pre-
infusion baseline and, therefore, could not be correlated with BOLD re-
sponses.We endedupwith data for n=6 for hunger, and n=7 for full-
ness, in these models. In the included subjects, the increase in fullness
and reduction in hunger were very small in magnitude and blood and
VAS scores were collected at 5 min intervals, therefore there was less
temporal resolution in comparison to the initial BOLD analysis which
was done using 2 minute time bins. The small magnitude of change
in VAS scores was not unexpected, since it is well established that
intragastric infusion has less potent effects on appetite perceptions
than oral consumption (Cecil et al., 1998). Future work using this
paradigm should investigate the effects of these additional compo-
nents during meal ingestion.
Of interest, it has recently been shown that GLP-1 in response to lipid
is inhibited by dexloxiglumide indicating dependence on CCK receptor
activation (Beglinger et al., 2010). This dependence does not appear to
be the case in response to glucose stimulation and probably implicates
a direct action of glucose on GLP-1 producing enteric mucosal cells.
The other brain regions responding to glucose, including the cerebel-
lum, thalamus, precuneus and motor cortex have been consistently
demonstrated in our previous studies to respond to nutrient ingestion
and or gut hormones (i.e. ghrelin) (Jones et al., 2012; Lassman et al.,
2010), suggesting that they play a role in mediating the gastrointestinal
and appetite responses to ingested food. In particular, the cerebellum
10 T.J. Little et al. / NeuroImage 96 (2014) 1–11has been shown to play an important role in food intake (Zhu and
Wang, 2008).
In conclusion this study provides important new information about
whole brain responses to intragastric glucose inman, and demonstrates
that multiple mechanisms operate to modulate BOLD signal in the
nutrient-induced brain matrix.
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